NYU Langone Health

In a 31-center phase 2 trial in 10 countries, apecotrep BI 764198 reduced proteinuria in patients with primary focal segmental glomerulosclerosis.

New research in patients with end-stage kidney disease suggests an association between neighborhood advantage and access to transplants and waitlists.

In 2025, FDA approvals, pivotal trials, and emerging therapies shifted nephrology care toward precision and mechanism-driven kidney medicine.

Historic progress in renal xenotransplantation in 2025 brings pig kidney transplants closer to clinical reality amid an ongoing donor organ shortage.

Bariatric surgery, particularly sleeve gastrectomy, may improve survival and kidney transplant access in older adults with obesity and ESKD.

Data presented at NASPGHAN 2025 revealed odevixibat demonstrated sustained improvements in sleep and caregiver-reported QOL in patients with Alagille syndrome through 96 weeks.

Among patients with primary hyperoxaluria and CKD, those with delayed CKD diagnosis were more likely to encounter greater healthcare burdens.

The expert panel concludes its discussion with insights on how collaboration and communication across various healthcare specialties improve the care of patients treated for iron deficiency anemia.

The panel discusses the mechanism of treatment-emergent hypophosphatemia that occurs following the administration of certain intravenous iron formulations.

Experts on iron deficiency anemia discuss practical tools they utilize for the clinical administration of intravenous iron.

Steven Fein, MD, MPH, shares insights on the management of infusion reactions seen in patients receiving intravenous iron.

Layla Van Doren, MD, discusses the management of complement activation-related pseudo-allergy (CARPA) in patients receiving intravenous iron infusions.

A panel of experts on iron deficiency anemia discuss the safety of intravenous iron infusions, highlighting data from clinical studies.

Experts on iron deficiency anemia share clinical practices for patients receiving intravenous iron.

Michael Auerbach, MD, provides an overview of the utility of generic formulations of iron in addressing iron deficiency anemia.

A panel of experts on iron deficiency anemia discusses formulations available for iron infusions, highlighting factors that inform selection.

Experts in hematology, gastroenterology, and obstetrics and gynecology detail their experiences with the real-world application of intravenous iron in their clinics.

An obstetrician-gynecologist addresses the unmet clinical needs in the treatment of patients with iron deficiency anemia, particularly for pregnant patients.

The expert panel discusses why intravenous iron replacement used to be associated with unacceptable toxicity and has become much more tolerable over time.

The panel provides a broad overview of the treatment of patients with iron deficiency, highlighting diagnostic practices.

A panel of experts on iron deficiency anemia introduce themselves and provide an overview of the physiology of iron metabolism and iron deficiency.

Dr David Hudesman, Dr Jordan Axelrad, and Dr Jose Scher discuss strategies for managing coexisting inflammatory bowel disease and psoriatic arthritis and highlight the importance of a multidisciplinary approach to providing comprehensive care.

The approval of risankizumab represents the first ever IL-23 approved by the FDA for IBD.

"The best test is the 1 that gets done," Williams said.

NYU Langone Health has been recognized as No. 1 in quality and safety for inpatient and ambulatory care by Vizient, Inc. On Wednesday, September 21, 2022.

Dr. David Hudesman expects drug developers to continue to target biologics for the treatment of IBD.

Machine learning algorithms successfully predicted visual and anatomic outcomes and dosing frequency in patients with macular edema secondary to CRVO.

Event rates were inversely proportional to kidney function in patients with chronic coronary disease.

Once a day readings over a year would detect 98.3% of the first Afib >24 hour episodes, while the probability of ≥1 false positive reading would be 98%.

Dr. Modi discusses the pending approval of faricimab for nAMD, DME treatment and highlights important observations from phase 3 data.